CJC with or without DAC?
CJC-1295 with DAC
CJC-1295 with DAC vs. CJC-1295 without DAC: Clinical & Research Differences with a Focus on GH Pulsatility
YouTube summary
CJC-1295 is a growth hormone–releasing hormone (GHRH) analog. Attaching a Drug-Affinity Complex (DAC) enables albumin binding and markedly prolongs half-life. In contrast, the non-DAC (short-acting) form—commonly referred to as Mod GRF(1-29)—has a brief plasma life and produces transient, pulse-like GH elevations. These pharmacokinetic distinctions shape whether GH output is sustained or pulsatile, with implications for physiologic signaling.
Product page for laboratory research: CJC-1295 (Research Use Only) .
Head-to-Head Comparison
Design
Albumin-binding via DAC → long-acting GHRH analog
Short-acting GHRH(1-29) analog without albumin binding
Half-life / Exposure
Prolonged exposure (days) with sustained GH/IGF-1 rise in humans1
Minutes; brief spikes in plasma → transient GH pulses
GH Secretion Pattern
Elevates basal GH and augments pulses, trending toward a more tonic profile under continuous exposure1
Primarily pulsatile bursts when dosed intermittently, aligning with physiologic ultradian GH rhythms2
Physiologic Relevance
Useful for sustained stimulation; may blunt relative pulse amplitude depending on background somatostatin tone
Better preserves timing-dependent physiology and receptor recovery windows described for normal GH neuroendocrine control2
Downstream Readouts
Clear increases in circulating IGF-1 over days to weeks in early clinical studies1
Short-window GH/IGF-1 excursions; magnitude depends on dose timing and co-secretagogues
Why Pulsatility Matters
Human GH physiology is governed by alternating hypothalamic GHRH and somatostatin signals that create ~8–12 pulses per 24 h. Pulses are thought to optimize receptor signaling, hepatic IGF-1 generation, and downstream metabolic effects. Short-acting GHRH analogs can be timed to reinforce natural peaks, whereas long-acting exposure tends to raise mean GH/IGF-1 more steadily but may flatten the relative pulse amplitude in some settings.2
Implications for Study Design (Research-Only)
Endpoints: 12–24 h GH profiling (deconvolution), IGF-1, and pulse metrics (frequency, mass, interpulse interval).
Dosing Logic: Non-DAC analogs enable time-of-day strategies to probe physiologic alignment; DAC enables exposure-response studies over days.
Context: Background somatostatin tone, sleep status, caloric state, and co-secretagogues (e.g., ghrelin mimetics) can materially alter outcomes.
Maintain sourcing consistency for comparability: CJC-1295 — research page.
References (max 2)
Teichman SL, et al. Prolonged stimulation of GH and IGF-1 by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. (Demonstrates albumin binding, extended half-life, and sustained IGF-1 response in humans.)
Veldhuis JD, Bowers CY. Human GH pulsatility: regulation and clinical implications. Endocrine Reviews. 2003;24(6): 782-793. (Overview of physiologic pulsatile GH control and the roles of GHRH and somatostatin.)
Compliance & Research-Only Notice
Pure Tested Peptides supplies compounds strictly for laboratory research use only. All information above is for educational and scientific discussion. Products are not medicines or drugs, are not intended for human consumption, and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease.